DPP-4 Inhibitors and Acute Myocardial Infarction:Effects on Platelet Function

• Status: Completed
• Trial end date: 2020-02-28
• Target enrollment: 0
• Participant gender: All

Summary

Cardiovascular events are the main cause of mortality in diabetic patients ,on the other hand,during an acute myocardial infarction(AMI),hyperglycemia increases mortality and is related to different pathophysiologic processes.

More important evidence regarding the effect of glycemic control on AMI patients prognosis is contradictory,and the potential benefits of dipeptidyl peptidase-4 inhibitors(DPP4-i) in this setting is unknown.

The aim of this study is to assess the presence of pleiotropic effects of DPP4-i(sitagliptin or saxagliptin) and their relationship with glycemic control during in-hospital phase of AMI.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Sao Paulo General Hospital
• Collaborator: InCor Heart Institute
• Treatments: Saxagliptin; Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• previous diagnosis of type 2 diabetes mellitus,with treatment including insulin and/or oral antidiabetic agent;

• subjects without previous diagnosis of diabetes,but HbA1c admission >= 6,5% during current hospital-stay

• AMI with or without ST-elevation;

• use of double antiplatelet therapy;

• signed informed consent term

Exclusion Criteria:

• GFR <30 ml/min;

• use of DPP4 inhibitors or glucagon- like peptide-1(GLP1) analogue in the past 6 months;

• use of strong inhibitors of cytochrome P450(CYP3A4/5) ou glucocorticoids;

• severe systemic decompensation requiring insulin infusion;

• Killip classification of myocardial infarction grade >2;

• previous history of pancreatitis